Evidence mapPaperPMID 40913714Full record

ReviewProbiotics and antimicrobial proteins2026

Bridging the Gut Microbiota and the Brain, Kidney, and Cardiovascular Health: The Role of Probiotics.

Milena Rosa Lopes, Rosa Direito, Elen Landgraf Guiguer, Vitor Cavallari Strozze Catharin, Tereza Lais Menegucci Zutin, Claudio José Rubira, Virgínia Maria Cavallari Strozze Catharin, Kátia Portero Sloan, Lance Alan Sloan, José Luiz Yanaguizawa Junior and 3 more

Abstract readReview
In one paragraph

Review in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Milena Rosa LopesDepartment of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília, SP, 17525-902, Brazil.
Rosa DireitoLaboratory of Systems Integration Pharmacology, Clinical and Regulatory Science, Research Institute for Medicines (iMed.ULisboa), Universidade de Lisboa, 1649-003, Lisbon, Portugal. rdireito@ff.ulisboa.pt.
Elen Landgraf GuiguerDepartment of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília, SP, 17525-902, Brazil.
Vitor Cavallari Strozze CatharinDepartment of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília, SP, 17525-902, Brazil.
Tereza Lais Menegucci ZutinDepartment of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília, SP, 17525-902, Brazil.
Claudio José RubiraDepartment of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília, SP, 17525-902, Brazil.
Virgínia Maria Cavallari Strozze CatharinDepartment of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília, SP, 17525-902, Brazil.
Kátia Portero SloanDepartment of Clinical Metabolism, Texas Institute for Kidney and Endocrine Disorders (TIKED), Lufkin, TX, 75904, USA.
Lance Alan SloanDepartment of Clinical Metabolism, Texas Institute for Kidney and Endocrine Disorders (TIKED), Lufkin, TX, 75904, USA.
José Luiz Yanaguizawa JuniorDepartment of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília, SP, 17525-902, Brazil.
Lucas Fornari Laurindo *Department of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília, SP, 17525-902, Brazil.
Sandra Maria Barbalho *Department of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília, SP, 17525-902, Brazil.
Ricardo de Alvares Goulart *Department of Biochemistry and Pharmacology, School of Medicine, Universidade de Marília (UNIMAR), Marília, SP, 17525-902, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The symbiosis between intestinal bacteria and the human body's physiological processes can modulate health. The intestinal microbiota is linked to the development of neurotrophic factors; therefore, it is increasingly related to the modulation of nervous system pathologies. Moreover, microbiota can interfere with inflammation and oxidative stress, which are closely linked to cardiovascular risk factors and several other inflammatory conditions, such as kidney and neurodegenerative diseases. Probiotics are live microorganisms that help regulate and maintain healthy microbiota; thus, they can help prevent these diseases. Due to these reasons, this review aimed to evaluate the effects of probiotics on the gut, kidneys, brain, and heart homeostasis. Clinical trials showed several positive results with the treatment. In the brain, probiotics reduce depressive symptoms (decreases in HAMA, GAD-7, and BDI-II scales), improving patients' sleep quality and fatigue, enhancing cognitive subscales while slowing brain atrophy, and reducing IL-6 levels in the central areas, also modulating REM delta power to reduce high-frequency brain waves. Probiotics can also reduce cardiovascular risk factors, such as inflammation. Probiotics can also benefit the heart by decreasing TMAO, LDL-c, TG, CRP, MDA, TNF-α, IL-6, and urea levels, improving dyslipidemia and toxin profiles. Probiotics also increase HDL-c, ApoE, and insulin sensitivity, decreasing BMI, body fat, and the risk of developing chronic hyperglycemia while increasing lean mass. Besides, probiotic supplementation helped reduce toxic uremic toxins (serum urea) and sodium levels, bringing benefits to the kidneys, and improve energy/amino acid metabolism. Probiotics can also modulate and enhance kidney function due to decreased pro-inflammatory TGFβ-1 and TNF-α levels and RUNX2. Furthermore, enhanced gastrointestinal motility and diversity have been reported using specific bacteria. Although probiotics can bring several health benefits, there are still challenges regarding these supplements, such as dose, frequency, and pharmaceutical formula. Therefore, new studies are welcome to deepen the understanding of these microorganisms.

Indexed as

BrainCardiovascular DiseasesCardiovascular SystemGastrointestinal MicrobiomeKidneyProbioticsAnimalsHumansGut-brain-kidney-heart axisInflammationOxidative stressProbiotics

Identifiers

PMID40913714
PMCPMC13176062

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.